mLumiOpto是一种针对线粒体的基因疗法,用于治疗癌症
Kai Chen1, Patrick Ernst2, Anusua Sarkar3
1Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio.
Cancer research
|September 17, 2024
概括
线粒体光因子遗传学 (mLumiOpto) 是一种针对癌细胞线粒体的新型基因疗法. 这种方法使用生物发光来激活通道罗多普辛,破坏线粒体潜力并诱导癌细胞死亡.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 线粒体在癌症的发展和进展中起着至关重要的作用.
- 向癌细胞线粒体提供治疗潜力,但有效的体内策略是有限的.
研究的目的:
- 开发和评估线粒体光因子遗传学 (mLumiOpto) 作为癌症的新型基因疗法.
- 通过破坏线粒体膜潜力来研究mLumiOpto诱导癌细胞死亡的能力.
主要方法:
- 开发了mLumiOpto,一种基因疗法,涉及线粒体内膜中的蓝光通道罗多普辛和细胞质纳米化酶.
- 在体内使用腺相关病毒 (AAV) 与癌症特异性促进体或向外体细胞传递mLumiOpto基因给癌细胞.
- 通过纳米化酶诱导的生物发光,在施用 luciferin 后激活通道 rhodopsin.
主要成果:
- mLumiOpto有效地破坏了线粒体膜潜力,导致癌细胞死亡.
- 在质母细胞瘤和三阴性乳腺癌异种移植模型中显著降低了瘤负担和癌细胞杀伤.
- 诱导了抗瘤免疫反应,由增加的树突细胞和CD8+ T细胞透证明.
结论:
- mLumiOpto是通过向线粒体来进行体内癌症治疗的有前途的治疗策略.
- 这种光遗传方法为诱导癌细胞死亡和减少瘤负担提供了一种新的方法.
更多相关视频
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.6K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:46Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K